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ttp://dx.doi.org/10.1016/j.ajpath.2014.05.004miRNAs have recently been implicated in hepatocarcinogenesis, although the actions and mechanisms
of individual miRNAs remain incompletely understood. We examined the biological functions and
molecular mechanisms of miR-185 in hepatocellular carcinoma (HCC). The expression of miR-185 is
decreased in human HCC tissues compared with the nonneoplastic liver parenchyma. Quantitative RT-
PCR showed a reduction of miR-185 in human HCC cells compared with primary hepatocytes. miR-185
overexpression in human HCC cells inhibited cell proliferation and invasion in vitro and prevented tumor
growth in SCID mice. miR-185 overexpression inhibited DNMT1 30 untranslated region luciferase reporter
activity in HCC cells; this effect was abolished when the miR-185 binding site was mutated. miR-185
mimic or overexpression decreased the level of DNMT1 protein in HCC cells. These ﬁndings establish
DNMT1 as a bona ﬁde target of miR-185 in HCC cells. The role of DNMT1 in miR-185einduced inhibition of
HCC growth was further supported by the fact that DNMT1 overexpression prevented miR-185einduced
inhibition of HCC cell proliferation/invasion. miR-185 mimic or overexpression reduced PTEN promoter DNA
methylation and enhanced PTEN expression, leading to the inhibition of Akt phosphorylation; these effects
were partially reversed by DNMT1 overexpression. These results provide novel evidence that miR-185 in-
hibits HCC cell growth by targeting DNMT1, leading to PTEN induction and Akt inhibition. Thus, reactivation
or induction of miR-185 may represent a novel therapeutic strategy for HCC treatment. (Am J Pathol 2014,
184: 2355e2364; http://dx.doi.org/10.1016/j.ajpath.2014.05.004)Supported by NIH grants CA106280, CA102325, CA134568, and
DK077776 (T.W.).
Disclosures: None declared.Hepatocellular carcinoma (HCC) is a highly malignant pri-
mary liver cancer with a poor prognosis.1e8 HCCs often
develop in the background of pre-existing chronic liver dis-
eases, such as chronic viral hepatitis B and C, alcoholic and
nonalcoholic steatohepatitis, and cirrhosis. The incidence of
HCC is rising in the United States and globally as a result of an
epidemic of chronic hepatitis C infection and other risk factors,
such as obesity and diabetes. Currently, HCC is the third
leading cause of cancer-associated death, with an estimated
continued rise in incidence during the next two decades.
Despite improvements in surgery and other treatments, the
overall 5-year survival rate for patients withHCC remains low.
Thus, further studies are needed to deﬁne the mechanisms of
hepatocarcinogenesis and develop new target therapies.
miRNAs are small noncoding RNA molecules that regu-
late gene expression post-transcriptionally through comple-
mentary base pairing with messenger RNAs.9 Recent studies
have shown an important role of miRNAs in the regulation of
HCC growth.10e16 Proﬁling of HCC miRNA expression hasstigative Pathology.
.identiﬁed signatures associated with diagnosis, staging,
progression, prognosis, and response to treatment. For
example, Budhu et al17 identiﬁed a 20-miRNA tumor
signature associated with HCC venous metastasis that can
predict HCC survival and recurrence in patients with multi-
nodular or solitary tumors; one of these miRNAs is miR-185.
A subsequent study by Zhi et al18 found that low miR-185
expression correlates with more tumor recurrence and a
lower patient survival rate compared with the high miR-185
group and that miR-185 reduces HCC cell growth and in-
vasion in vitro, suggesting that miR-185 may represent a
tumor-suppressive miRNA in HCC. However, to date, the
biological functions of miR-185 in hepatocarcinogenesis
remain largely unknown, and its mechanisms of action have
not yet been deﬁned.
Qadir et alThis study was designed to further examine the effect and
mechanism of miR-185 in human HCC. We show herein
that miR-185 is a tumor suppressor miRNA in HCC and that
its expression is down-regulated in human HCC tissues and
cells. Our ﬁndings indicate that miR-185 inhibits HCC cell
growth in vitro and in SCID mice by targeting the DNMT1/
PTEN/Akt signaling pathway.
Materials and Methods
Cells, Plasmids, and Reagents
Human hepatocellular cancer cell lines (HepG2, Huh7, and
Hep3B cells) were obtained from ATCC (Manassas, VA).
All the cell lines were cultured in Dulbecco’s modiﬁed
Eagle’s medium (Invitrogen, Carlsbad, CA) with 10% fetal
bovine serum (Sigma-Aldrich, St. Louis, MO). Primary
human hepatocytes were purchased from Lonza Inc. (Wal-
kersville, MD) and were cultured in collagen Iecoated
plates (BD Biosciences, Bedford, MA) with hepatocyte
basal medium supplemented with HCM SingleQuots growth
factors (Lonza Inc.). The cells were maintained at 37C and
5% CO2. The plasmids, including pcDNA3.1/DNMT1 and
pcDNA3.1, were purchased from Addgene Inc. (Cambridge,
MA). DNMT1 30 untranslated region (30-UTR) luciferase
reporter plasmid was purchased from OriGene Technologies
Inc. (Rockville, MD). Lentivirus encoding human miR-185
(L/miR-185) and control lentivirus expressing scramble
control miRNA (L/control) were purchased from GeneCo-
poeia Inc. (Rockville, MD). The antibodies against PTEN,
total Akt, and phospho-Akt (p-Akt) were obtained from Cell
Signaling Technology Inc. (Beverly, CA). The antibody
against b-actin was purchased from Sigma-Aldrich. The
anti-DNMT1 antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). 5-Aza-20-deoxycytidine
(5-Aza-CdR) and trichostatin A were obtained from Sigma-
Aldrich. Other chemicals were of analytical grade.
In Situ Hybridization for miR-185 in Human HCC Tissue
Specimens
In situ hybridization for miR-185 was performed in human
HCC tissue microarray (serial # LV8013; US Biomax Inc.,
Rockville, MD). The tissue microarray consisted of 80 tis-
sue core samples, including 20 cases of HCC, 10 cases of
liver cirrhosis, and 10 cases of normal liver tissue (each case
with duplicate samples) (more detailed information is
available from US Biomax Inc.). The tissue microarray was
prepared using the UVP HB-1000 Hybridizer hybridization
oven (UVP LLC, Upland, CA), designed to create the ideal
environment for nucleic acid hybridization. Human miR-
185 miRCURY LNA probes were purchased from Exiqon
Inc. (Woburn, MA), and the in situ hybridization procedure
was performed according to the manufacturer’s instruction.
A scramble miRNA control probe having no homology with
sequences in the miRBase database was used as a negative2356control. A U6 small nuclear RNA control probe was used as
a positive control. The U6 positive control and the scramble
negative control were used to ensure a functional working
system and for optimization and troubleshooting. The
staining score was measured by values from 0 to 4þ and
was categorized as no stainingZ 0, minimal stainingZ 1þ,
weak staining Z 2þ, moderate staining Z 3þ, or strong
staining Z 4þ.
Quantitative RT-PCR
Total RNA was extracted using a TRIzol plus RNA puri-
ﬁcation kit (Life Technologies Inc., Gaithersburg, MD) and
were reverse transcribed to cDNA using SuperScript II
reverse transcriptase (Life Technologies Inc.). The cDNA
samples were used for quantitative RT-PCR (RT-qPCR)
analysis in triplicate to determine the expression level of
miR-185 using a QuantiFast SYBR Green PCR kit (Qiagen
Inc., Valencia, CA) on a Bio-Rad C1000 thermal cycler
(Bio-Rad Laboratories, Hercules, CA). Experiments were
followed according to the manufacturer’s instructions.
Western Blot Analysis
The logarithmically growing cells were washed twice with
ice-cold phosphate-buffered saline and lyzed in a lysis buffer
(50 mmol/L Tris-HCl, pH 8.0; 150 mmol/L NaCl; 1%
Nonidet P-40 (Caledon Laboratories Ltd., Georgetown, ON,
Canada); 5 mmol/L EDTA, pH 8.0), with protease inhibitor
mixtures and phosphatase inhibitor from Roche Applied
Science (Indianapolis, IN). Cell lysates were centrifuged at
12,000 g for 20 minutes at 4C after sonication on ice, and
supernatants were collected to measure protein concentra-
tions. After boiling for 10 minutes in the presence of 10%
b-mercaptoethanol, samples containing cells or tissue lysate
proteins were separated by SDS-PAGE, transferred onto a
nitrocellulose membrane (Bio-Rad Laboratories), and then
blocked in 10% dry milk/phosphate-buffered saline with
0.1% Tween 20 for 1 hour at room temperature. The blots
were incubated with primary antibody (dilution 1:1000)
overnight at 4C. After three washes, the membranes were
incubated with secondary antibody (IRDye 680LT/IRDye
800CW secondary antibodies; Li-Cor Biosciences, Lincoln,
NE) in phosphate-buffered saline with 0.1% Tween 20
(dilution 1:10,000) for 60 minutes at room temperature or
4C overnight. Signals were visualized using the ODYSSEY
infrared imaging system (Li-Cor Biosciences). The anti-
bodies used include the following: DNMT1, PTEN, p-Akt,
total Akt, b-actin, and IRDye 680LT/800CW secondary an-
tibodies from Li-Cor Biosciences.
Tumor Cell Invasion Assay
Invasion studies were performed using the 24-well (8-mm),
colorimetric QCM ECMatrix cell invasion assay (EMD
Millipore, Billerica, MA) for the evaluation of invasive tumorajp.amjpathol.org - The American Journal of Pathology
miR-185 Inhibits HCC Growthcells. Warm serum-free medium was added to the interior of
the inserts to rehydrate the extracellular matrix layer for 1 to 2
hours. A Huh7 cell suspension of 1.0  106 cells/mL in
serum-free medium was prepared. Medium was removed
from the insert, and 300 mL of prepared cell suspension was
added to the insert. In addition, 500 mL of medium containing
10% fetal bovine serum was added to the lower chamber.
This 24-well plate was incubated for 24 hours in a tissue
culture incubator. Using a cotton-tipped swab, noninvaded
cells and ECMatrix gel (EMDMillipore) were removed from
the inserts. The invasive cells on the lower surface of mem-
brane were stained in staining solution for 20 minutes. The
membranes were dipped in water several times and allowed
to air-dry. Cells were counted by photographing the mem-
brane through the microscope.
Cell Proliferation
Cells were seeded in 6-well plates in quadruplicate in
standard growth medium. On the indicated days, the cells
were detached from the wells using 0.05% trypsin-EDTA
and were resuspended in 500 mL of standard growth me-
dium. Aliquots were mixed 1:1 with trypan blue stain and
were counted using a Countess automated cell counter
(Invitrogen). Cell numbers were counted at 24-, 48-, and 72-
hour time points. Triplicate measurement was performed for
each period, and the results are expressed as means  SD.
Selection of HCC Cells with Stable Overexpression of
miR-185
Huh7 cells were infected with L/miR-185 or L/control to
establish the stable cell lines in the presence of 6 mg/mL of
puromycin (Invitrogen). We monitored transfection efﬁ-
ciency by green ﬂuorescent protein signaling under a ﬂuo-
rescent microscope. Cells with stable overexpression of
miR-185 were conﬁrmed by real-time PCR.
Transient Transfection of miR-185 Mimic
Oligonucleotide
Using a 24-well plate, 1.0  105 Huh7 cells were seeded per
well in 500 mL of Dulbeco’s modiﬁed Eagle’s medium
containing 10% fetal bovine serum and antibiotics. These
Huh7 cells were transfected with double-stranded miR-185
mimic or its relative negative control RNA (Qiagen Inc.),
with a ﬁnal concentration of 5 nmol/L using Lipofectamine
2000 reagent in Opti-Mem I medium (both from Invitrogen)
for 24 hours. After transfection, these cells were collected
for Western blot analysis and real-time PCR experiments.
Overexpression of DNMT1 Devoid of the 30-UTR
Huh7 cells stably infected with miR-185 or control lentivirus
were seeded at 1.5 105 cells per well in a 24-well plate and
were transfected with pcDNA3.1 or pcDNA3.1-DNMT1The American Journal of Pathology - ajp.amjpathol.orgusing Lipofectamine 2000 for 24 hours. The resulting four
cell groups were used for DNMT1 rescue experiments.
DNMT1 30-UTR Luciferase Reporter Assay
DNMT1 30-UTR luciferase reporter plasmid was obtained
from OriGene Technologies Inc. Mutant DNMT1 30-UTR
luciferase reporter plasmid was constructed by cloning syn-
thetic DNMT1 30-UTR nucleotide (with deletion of the 7 bp
of hsaemiR-185 seed sequence) into the pMirTarget vector.
For transfection, Huh7 stable cells were seeded at 1.5  105
cells per well in a 24-well plate; 24 hours later, the cells were
transfected with the wild-type or mutant DNMT1 30-UTR
luciferase reporter plasmid using Lipofectamine 2000. The
cells were harvested 48 hours after transfection, and the
luciferase reporter activities were analyzed by using the
Dual-Luciferase reporter assay system (Promega Corp.,
Madison, WI) according to the manufacturer’s protocol.
PTEN Promoter Methylation Assay
PTEN tumor suppressor gene at þ1 transcription start site has
a CpG island region located 250 Bp upstream from the tran-
scription start site ofPTEN and overlaps in the PTEN promoter
region by 989 Bp, with a total length of 1239 Bp. The CpG
island region in the PTEN promoter was ampliﬁed by
methylation-speciﬁc PCR using primers that ampliﬁed a 186-
Bp fragment (this region has been shown to allow satisfactory
detection of PTEN promoter hypermethylation19). The
methylation status was assessed by using the EpiTect II DNA
methylation enzyme kit along with the EpiTect methyl qPCR
primer assay PTEN human (CpG island 28526) (both from
Qiagen Inc.) (the primers are located in the PTEN promoter
regionwith a central position on chromosome 10: 89613408 of
CpG island location Chr10: 89611752-89614108). The
method used was based on detection of the remaining input
DNA after cleavage with a methylation-sensitive and/or a
methylation-dependent restriction enzyme (these enzymes
digest unmethylated and methylated DNA, respectively). The
relative fractions of methylated and unmethylated DNA were
determined by comparing the amount in each digest with that
of a mock (no enzymes added) digest using a DCT method.
HCC Xenograft Study in SCID Mice
Four-week-old SCID mice from The Jackson Laboratory
(Bar Harbor, ME) were used for in vivo studies analyzing
tumor growth. A suspension of 1  107 live cells/mL was
mixed with BD Matrigel matrix high concentration (BD
Biosciences) in a 0.5-mL total volume for a 1:1 ratio. Five
microliters of cell suspension mixture was used for direct
liver injection using a Hamilton syringe (cemented NDL,
26s gauge, 2 in, point style 2) (model 75 N SYR; Hamilton
Co, Reno, NV). The high protein concentration (18 to 22
mg/mL) allowed the BD Matrigel matrix plug to maintain
its integrity after direct liver injections into the mice. This2357
Figure 1 Down-regulation of miR-185 in human HCC. A: Representative
in situ hybridization for miR-185 in human HCC and normal liver tissues.
The expression of miR-185 was decreased in HCC cells compared with
nonneoplastic hepatocytes. Boxed areas on the left correspond to higher-
magniﬁcation images on the right. B: miR-185 staining intensity in
different types of tissue specimens [normal liver, cirrhotic liver, hepatitis B
virus (HBV)eassociated HCC, and hepatitis C virus (HCV)eassociated HCC].
Staining intensities were compared and are depicted in a box plot. C: RT-
qPCR showed a lower level of miR-185 expression in human HCC cells
(Huh7, HepG2, and Hep3B) compared with human primary hepatocytes
(HHs). Data are given as means  SD. *P < 0.05, **P < 0.01. Original
magniﬁcation: 40 (A, left panels); 400 (A, right panels).
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2358allowed the injected tumor cells to remain localized for
future excision. The xenograft tumors were recovered 30
days after inoculation. Approximately 0.5 cm of tumor
samples were ﬁxed in 10% buffered formalin for parafﬁn
embedding. Tissue sections (4 mm thick) were processed for
hematoxylin and eosin staining. Immunostaining for the
proliferation marker Ki-67 was also performed. Portions of
the liver tumor samples were frozen in liquid nitrogen,
followed by 80C storage. Data analyses were performed
using a paired t-test. The animal experiments were per-
formed according to the protocol approved by the Tulane
University Institutional Animal Care and Use Committee.
Statistical Analysis
Statistical analyses were performed using SPSS forWindows
software, version 13.0 (SPSS Inc., Chicago, IL) and Micro-
soft Excel spreadsheet software (Microsoft Corp., Redmond,
WA). Xenograft tumors were analyzed using the paired t-test.
In situ hybridization results were analyzed using the U-test.
P  0.05 was considered statistically signiﬁcant.
Results
Decreased Expression of miR-185 in Human HCC Cells
We performed in situ hybridization for miR-185 in the
human liver tissue microarray consisting of 80 tissue sam-
ples (20 cases of HCC, 10 cases of cirrhotic liver, and 10
cases of normal liver; duplicate samples for each case).
Although miR-185 is readily detectable in nonneoplastic
hepatocytes, its level of expression is signiﬁcantly reduced
in HCC cells (Figure 1A). U-Test analysis revealed a sig-
niﬁcant reduction of miR-185 in HCCs arising from chronic
hepatitis C and/or chronic hepatitis B compared with the
normal liver tissues (there was no statistical signiﬁcance
between normal and cirrhotic liver tissues) (Figure 1B). This
observation is corroborated by the results of RT-qPCR
analysis showing decreased miR-185 expression in
cultured human HCC cells (Huh7, HepG2, and Hep3B)
compared with human primary hepatocytes (Figure 1C).
DNMT1 Is a Direct Target of miR-185
We performed in silico analyses for target gene prediction by
using Target Scan Human software version 5.2 and the re-
sources from http://www.microRNA.org (last accessed August
24, 2011), which led to the identiﬁcation of DNA (cytosine-5)-
methyltransferase 1 (DNMT1) as one of the high-scoring
candidate genes of miR-185 targets. Consequently, we per-
formed further experiments to evaluate the effect of miR-185
on DNMT1 in HCC cells. Transient transfection of miR-185
mimic signiﬁcantly decreased the level of DNMT1 in Huh7
and HepG2 cells (Figure 2). Similarly, stable transduction of
Huh7 cells with an L/miR-185 also signiﬁcantly decreased
DNMT1 protein levels (successful overexpression of miR-185
was conﬁrmed by RT-qPCR) (Figure 3, A and B). Moreover,ajp.amjpathol.org - The American Journal of Pathology
Figure 2 miR-185 targets DNMT1 in HCC cells.
Huh7 (A) and HepG2 (B) cells were transiently
transfected with miR-185 mimic and miRNA
scramble control oligonucleotide. The cell lysates
were obtained for Western blot analysis to measure
DNMT1 protein levels. DNMT1 protein expression
was analyzed with b-actin as an internal control.
The experiments were repeated ﬁve times (NZ 5).
Normalized fold expression of DNMT1 in Huh7 cells
transfected with miR-185 mimic was compared
with scramble control as depicted in bar graphs.
Data are given as means  SD. *P < 0.05.
miR-185 Inhibits HCC GrowthHuh7 cells stably overexpressing miR-185 showed a signiﬁ-
cant reduction of cell proliferation and invasion (an approxi-
mately fourfold reduction of cell proliferation; an
approximately 50% decrease of cell invasion) (Figure 3, C and
D). These results demonstrate that miR-185 targets DNMT1
and inhibits HCC cell growth in vitro.
We identiﬁed a putative miR-185 binding site in the 30-
UTR of DNMT1 (Figure 4A); this binding site is located atThe American Journal of Pathology - ajp.amjpathol.orgpositions 306 to 312 of DNMT1 30-UTR. To determine
whether this predicated site is involved in miR-185 targeting
of DNMT1 in HCC cells, we transfected luciferase reporter
constructs containing DNMT1 30-UTR (with or without miR-
185 binding site mutation) into Huh7 cells (with or without
miR-185 overexpression). miR-185 overexpression signiﬁ-
cantly reduced the DNMT1 30-UTR luciferase reporter ac-
tivity (by 2.3-fold), and the effect was abolished when theFigure 3 miR-185 targets DNMT1 and inhibits
HCC proliferation and invasion in vitro. A: Real-
time PCR quantiﬁcation of miR-185 showed a sig-
niﬁcant increase in Huh7 cells stably transduced
with L/miR-185 compared with cells stably trans-
duced with L/Control. B: Western blot analysis for
DNMT1 in Huh7 cells with or without stable over-
expression of miR-185. Representative Western
blots and average densitometry data. The level of
DNMT1 protein is decreased in Huh7 cells stably
expressing miR-185 (gray bars) compared with
control cells (white bars). C: Cell proliferation was
measured at 24, 48, and 72 hours in Huh7 stable
cells after plating 1  103 per well in 6-well plates.
miR-185 overexpression decreased cell prolifera-
tion at all the time points. D: A cell invasion assay
was performed in Huh7 stable cells. Huh7 miR-185
stable cells showed an approximately 50% reduc-
tion in the number of invaded cells on the matrix
membrane surface compared with control after 24
hours. The images depict invaded cells. Data are
given as means  SD. N Z 5 (B). *P < 0.05,
**P < 0.01, and ***P < 0.001.
2359
Figure 4 miR-185 decreases DNMT 30-UTR luciferase reporter activity in
HCC cells. A: The putative miR-185 binding site in DNMT1 30-UTR is depicted
in the top sequence pairs. The original strand of DNMT1 30-UTR contains the
7-Bp seed sequences that bind to miR-185; the DNMT1 30-UTR mutant
strand shows deletion of the 7-Bp seed sequence. B: DNMT1 30-UTR lucif-
erase reporter acidity assay in Huh7 stable cells transfected with wild-type
or mutant DNMT1 30-UTR reporter construct. Data are given as means  SD.
N Z 3. *P < 0.05.
Qadir et almiR-185 binding site was mutated (Figure 4B). Thus,
DNMT1 is a bona ﬁde target of miR-185 in HCC cells.
Restoration of DNMT1 Prevents miR-185eInduced
Inhibition of HCC Cell Proliferation and Invasion
To further determine the role of DNMT1 in miR-
185einduced inhibition of HCC growth, we transfected
miR-185 overexpressed cells with a DNMT1 expression
vector devoid of the 30-UTR. Speciﬁcally, Huh7 stable cells
(with or without miR-185 overexpression) were transfected
with a DNMT1 expression vector (DNMT1 in pcDNA3) or
a control vector (pcDNA3), and the cells were analyzed for
proliferation and invasion. DNMT1 overexpression pre-
vented miR-185einduced inhibition of cell proliferation and
invasion (Figure 5).
miR-185 Regulates the PTEN/Akt Signaling Pathway in
HCC Cells
DNMT1 is essential for maintaining DNA methylation
patterns during carcinogenesis and is important for cancer
cell survival and proliferation.20e22 The effect of DNMT is
mediated, in part, through methylation of 50-CpGs of target
gene promoters, thus silencing the expression of tumor
suppressor genes (including PTEN ).23,24 We performed a
methylation-speciﬁc PCR assay to determine the extent of
DNA methylation in the PTEN promoter region. Stable
overexpression of miR-185 in Huh7 cells signiﬁcantly
reduced PTEN promoter DNA methylation (Figure 6A).
miR-185 mimic treatment enhanced the expression of PTEN
protein in Huh7 cells (Figure 6B) and HepG2 cells
(Supplemental Figure S1). Consistent with the documented
inhibition of Akt phosphorylation by PTEN, we observed
decreased levels of p-Akt in miR-185 mimicetreated cells.
Furthermore, stable overexpression of miR-185 also
enhanced PTEN protein and inhibited Akt phosphorylation;
these effects were partially reversed by overexpression of
DNMT1 (devoid of the 30-UTR) (Figure 5A). We observed
that inhibition of DNMT by 5-Aza-CdR also decreased
PTEN promoter methylation, enhanced PTEN protein, and
reduced Akt phosphorylation (Supplemental Figure S2),
which are comparable with those induced by miR-185
mimic or overexpression. Taken together, these ﬁndings
suggest that miR-185 inhibits HCC cell growth by targeting
DNMT1, which leads to induction of PTEN expression and
subsequent inhibition of Akt phosphorylation. This asser-
tion is further corroborated by the documented role of PTEN
and Akt in hepatocarcinogenesis.25e29
Because the established epigenetic/global methylatione
regulated tumor suppressor genes in patients with HCC
include p14ARF, p16INK4A, and SOCS-1,30 we further
examined the levels of these proteins in our systems. We
observed that the protein levels of p14ARF, p16INK4A, and
SOCS-1 were signiﬁcantly higher in Huh7 cells treated with
5-Azad-CdR compared with cells treated with vehicle2360control (Supplemental Figure S3). However, lentiviral viral
transduction of miR-185 in Huh7 cells did not signiﬁcantly
alter the protein levels of p14, p16, and SOCS-1. Similarly,
the protein levels of p14ARF, p16INK4A, and SOCS-1 in
miR-185 overexpressed Huh7 xenograft tumors were not
signiﬁcantly different compared with the control tumors.
Thus, miR-185 does not seem to inﬂuence the levels of
p14ARF, p16INK4A, and SOCS-1 in our system, despite that
miR-185 targets DNMT1. The explanation for the latter
phenomenon is unknown and remains speculative. We
cannot exclude the possibility that miR-185 might inﬂuence
these molecules through indirect mechanisms that are yet to
be identiﬁed. It is also possible that the observed phenom-
enon may reﬂect cell typeespeciﬁc changes. Nonetheless,
the ﬁndings in this study support the involvement of
DNMT1-regulated PTEN in miR-185emediated inhibition
of HCC cell growth.miRNA-185 Inhibits HCC Growth in Vivo
To determine the effect of miR-185 on HCC growth in vivo,
we inoculated Huh7 cells stably expressing miR-185 orajp.amjpathol.org - The American Journal of Pathology
Figure 5 Restoration of DNMT1 prevents miR-
185einduced inhibition of HCC cell proliferation
and invasion. A: Western blot analysis for DNMT1,
PTEN, p-Akt, and Akt in Huh7 stable cells with or
without DNMT1 overexpression. B: Cell prolifera-
tion analysis of Huh7 stable cells with or without
DNMT1 overexpression. The experiments were
performed 72 hours after plating 1  103 per well
in 6-well plates. The experiments were repeated
three times. C: Cell invasion assay of Huh7 stable
cells with or without DNMT1 overexpression. The
numbers of invaded cells were counted 24 hours
after cell plating. The images depict invaded cells.
Data are given as means  SD. N Z 5 (A); N Z 3
(B and C). *P < 0.05.
Figure 6 miR-185 decreases PTEN promoter methylation and enhances
PTEN expression in Huh7 cells. A: Huh7 cells stably infected with miR-185 or
control lentivirus were subjected to methylation-speciﬁc PCR assay. miR-185
overexpression decreased methylation in the PTEN CpG island promoter re-
gion. B: Huh7 cells were transiently transfected with miR-185 mimic and
scramble control oligonucleotide, and the cell lysates were obtained for
Western blot analysis to determine the levels of PTEN, p-Akt, and Akt. Data are
given as means  SD. NZ 5. *P < 0.05.
miR-185 Inhibits HCC Growthscramble control miRNA into the livers of SCID mice [direct
intrahepatic inoculation was achieved by injecting cell sus-
pension mixed with Matrigel solution (BD Biosciences)]; the
animals were observed for 30 days to monitor for tumor
growth in the liver. The cells overexpressing miR-185
formed smaller tumor nodules in the liver compared with
the controls (an approximately 11-fold decrease in tumor
volume) (Figure 7A). Immunostaining for the cell prolifera-
tion marker Ki-67 showed a reduction of Ki-67epositive
cells in miR-185 overexpressed tumors (Figure 7B). Western
blot analysis conﬁrmed a reduction of DNMT with up-
regulation of PTEN and a decrease of p-Akt in miR-185
overexpressed tumor tissues (Figure 7C). These results
demonstrate that miR-185 inhibits HCC growth in vivo.
Discussion
This study provides novel evidence that miR-185 is a tumor-
suppressive miRNA that inhibits HCC cell growth by
targeting DNMT1. This assertion is based on several
observations: i) the expression of miR-185 is decreased in
human HCC tissues and cell lines compared with the non-
neoplastic hepatocytes; ii) forced overexpression of miR-
185 in human HCC cells inhibits tumor cell growth in vitro
and in SCID mice; iii) miR-185 directly targets DNMT1, a
key enzyme that silences the expression of tumor suppressor
genes (including PTEN ); iv) overexpression of DNMT1
devoid of the 30-UTR prevents miR-185einduced inhibition
of HCC cell proliferation and invasion; v) miR-185 mimic
or overexpression reduces PTEN promoter DNA methyl-
ation and restores PTEN expression (leading to Akt inhi-
bition), and these effects are partially reversed by forced
overexpression of DNMT1; and vi) the effects of miR-185The American Journal of Pathology - ajp.amjpathol.orgmimic or overexpression on PTEN in HCC cells are similar
to those induced by the DNMT inhibitor 5-Aza-CdR. These
ﬁndings demonstrate that miR-185 inhibits HCC cell growth
by targeting DNMT1, which leads to induction of PTEN and
inhibition of Akt (Figure 7D).
Budhu et al17 reported that miR-185 is one of the 20 miR-
NAs associated with HCC venous metastasis that can predict
HCC survival and recurrence. They identiﬁed miR-185 as one2361
Figure 7 miR-185 overexpression inhibits HCC growth in SCID mice. An Huh7 stable cell suspension mixed in Matrigel
solution was inoculated into SCID mice via direct liver injections. A: Gross images depict liver tumors that originated from
miR-185 overexpressed or control cells. Local liver tumors that originated from miR-185etransduced Huh7 cells are
signiﬁcantly smaller (11-fold decrease) in tumor volume compared with control. B: Ki-67 immunostaining showed a lower
proliferative rate in miR-185 overexpressed tumors compared with the control. C: Western blot analysis for DNMT1, PTEN,
and p-Akt in miR-185 overexpressed or control tumors recovered from the livers of SCID mice. Normalized fold expressions
for DNMT1, PTEN, and p-Akt are depicted in bar graphs. D: Schematic illustration of miR-185einduced inhibition of HCC
growth. Data are given as means  SD. N Z 12 (A); N Z 5 (C). *P < 0.05.
Qadir et alof the four miRNAs that are up-regulated in HCCs with
venous metastasis compared with HCCs without venous
metastasis (16 miRNAs were found to be down-regulated in
HCCs with venous metastasis compared with HCCs without
venous metastasis); however, whether these miRNAs differ
between HCC and nontumorous liver tissues was not
addressed. Zhi and colleagures18 found that low miR-185
expression in early-stage HCC correlated with more tumor
recurrence and worse patient survival compared with the
high miR-185 group; the latter study also did not address
whether miR-185 differed between HCC and nontumorous
liver tissues. Therefore, the role of miR-185 in venous
metastasis and in HCC recurrence seems conﬂicting, with
high miR-185 expression found to be associated with
venous metastasis but less tumor recurrence and better pa-
tient survival. Although it is possible that multiple factors
might have contributed to the discrepancy (including
different patient populations, different tumor stages,
different parameters analyzed, and different study designs),
an important pitfall is that in both of the previous studies,
the levels of miR-185 in HCC tissues were measured by
RT-qPCR, which prevents comparison of their levels in2362different cell populations in the tumor microenvironment.
This is an important issue given that miRNAs in different
cell populations in the tumor microenvironment may
mediate distinct functions.15,16 In this context, the in situ
hybridization technique used in the present study allows
direct comparison of miR-185 in HCC and nonneoplastic
liver parenchymal tissues. These data indicate that in non-
neoplastic liver parenchyma, miR-185 is predominantly
expressed in hepatocytes, whereas its expression is signiﬁ-
cantly reduced in neoplastic hepatocytes. This observation
is further corroborated by the RT-qPCR analysis showing
decreased miR-185 expression in cultured human HCC cell
lines compared with primary human hepatocytes. These
results, along with the functional and mechanistic studies
described herein, demonstrate that miR-185 is a tumor
suppressor miRNA that inhibits HCC growth.
Another important aspect of the present study is the iden-
tiﬁcation of DNMT1 as the direct target of miR-185 in human
HCC cells. DNMT1 is the most abundant DNMT in
mammalian cells (including hepatocytes) that catalyzes the
methylation of cytosine at the 50 position, forming 50-meth-
ylcytosine; it is responsible for de novo and maintenanceajp.amjpathol.org - The American Journal of Pathology
miR-185 Inhibits HCC Growthmethylation of tumor suppressor genes in cancer cells.31,32
The notion that miR-185 directly targets DNMT1 is sup-
ported by the observations that i) a putative miR-185 binding
site is present in the 30-UTR of DNMT mRNA; ii) miR-185
mimic or overexpression decreased DNMT1 protein levels
in HCC cells; iii) miR-185 overexpression signiﬁcantly
reduced the DNMT1 30-UTR luciferase reporter activity in
HCC cells, and the effect was abolished when the miR-185
binding site was mutated; and iv) restoration of DNMT1
prevented miR-185einduced inhibition of HCC cell prolif-
eration and invasion.
DNMT catalyzes the methylation of cytosine at the CpG
islands of tumor suppressor genes (including PTEN ).33
Although CpG islands are usually present in an unmethylated
state, DNMT enzyme activity leads to conversion to the meth-
ylated status, resulting in suppression of gene transcription.34
Accordingly, hypermethylation of tumor suppressor gene pro-
moters has been recognized as an important mechanism in
hepatocarcinogenesis.35,36 In the present study, we found that
miR-185mimic or overexpression reducedDNAmethylation in
thePTENpromoter and enhancedPTENprotein expression, and
these effects were reversed by forced overexpression of
DNMT1. In addition, we note that the effects of miR-185mimic
or overexpression on PTEN promoter DNA methylation and
protein expression in HCC cells are comparable with the effect
induced by the DNMT inhibitor 5-Aza-CdR. These ﬁndings
suggest that miR-185 prevents HCC growth through inhibition
of DNMT protein synthesis, thus restoring PTEN expression.
Consistentwith the documented role of PTEN in the suppression
of Akt phosphorylation, we observed that miR-185 mimic or
overexpression decreased Akt phosphorylation in HCC cells.
These ﬁndings are consistent with the well-documented sup-
pression of PTEN and activation of Akt in HCC.25e29
The relationship between epigenetic and miRNA regulation
has been increasingly providing a better understanding of the
development and progression of human cancers.37,38 Epige-
netic modiﬁcations include DNA methylation, histone modi-
ﬁcations, and RNA-based mechanisms in which miRNAs are
critically implicated. In this context, it is noteworthy that the
present study provides novel evidence for an important tumor-
suppressive role of miR-185 in HCC through targeting
DNMT, a key enzyme in cancer epigenetics.
In summary, this study provides novel evidence that miR-
185 is a tumor suppressor miRNA that inhibits HCC cell
growth by targeting DNMT1 and up-regulating PTEN
expression. Therefore, reactivation or induction of miR-185
may represent a novel therapeutic strategy for HCC treat-
ment that warrants further investigation. Furthermore, it
remains to be determined whether miR-185 and DNMT can
be concomitantly targeted for effective anti-HCC therapy.
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